Skip to main content
Follow Gene Therapy Net on X LinkedIn - Gene Therapy Net discussion group Facebook - Gene Therapy Net
 
Gene Therapy Net Newsletter  
genetherapynetbanner468x60

­

News: First patient in the Netherlands successfully treated with stem cell gene therapy

­

Researchers from the Leiden University Medical Center (LUMC) have successfully used stem cell gene therapy to treat a baby with the severe congenital immune disorder SCID. An important milestone: it is the first time stem cell gene therapy of Dutch origin has been administered to a patient, and also the first time it has been used to treat this particular form of SCID worldwide. The treatment was effective and the patient is doing well.

Read more…

­

­

­

News: Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma

­

Novartis has acknowledged that two patients have died of acute liver failure following treatment with its Zolgensma® (onasemnogene abeparvovec-xioi), a one-time gene therapy indicated for some forms of spinal muscular atrophy (SMA). As a result, the company said, it will revise Zolgensma’s label to specify that fatal acute liver failure has been reported.

Read more…

­

­

­

Conference: 3rd Annual Gene Therapy for Ophthalmic Disorders

­

As Luxturna is still the only FDA approved gene therapy for the eye, the question remains - which drug will be the next to change the lives of patients with ophthalmic disorders? The industry is working tirelessly to provide these highly valuable drugs to those who need them. With inspiring series A funding for SpliceBio, and a new collaboration between ViGeneron and Regeneron, as well as unexpected clinical setbacks seen with ProQR, 2022 has been full of learning opportunities year for the industry.
Join the 3rd Annual Gene Therapy for Ophthalmic Disorders Summit (September 13-16, Boston) to tackle the pressing challenges faced in the preclinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.
40+ speakers from the industry leaders in ophthalmic gene therapy will be attending, such as Adverum, REGENXBIO, Novartis, Janssen, Kriya, Nanoscope, IVERIC, GenSight, SparingVision, Atsena, AGTC, ViGeneron, as we discover novel vector engineering, disease models, clinical trials design and patient enrolment platforms.
Register now…

­

­

­

Conference: Cell & Gene Therapy Manufacturing & Commercialization US

­

The cell, gene & immunotherapy event for improving manufacturing efficiencies, costs, and quality. Attend to hear from 100+ of the industry's top scientists to present the latest updates on how to improve efficiencies across all phases of Cell & Gene Therapy development and production. Join us in Boston, Massachusetts or digitally on September 27-30, 2022. Enjoy a 10% discount by registering to our event using the link below.

Register now…

­

­

­

Conference: 4th Exosome Based Therapeutic Development Summit

­

With 3 days of unrivalled content and two dedicated tracks, this year’s Exosome Based Therapeutic Development summit (October 4-6, 2022) will be putting the spotlight on cutting-edge strategies from discovery, translation, and clinical development of modified and unmodified exosomes and EVs, to accelerate this emerging field forward.

Tailor-made to showcase the latest innovations and interactively discuss the industry’s most important talking points, join 130+ movers and shakers of the field from the likes of Codiak BioSciences, Rion, MDimmune and Aruna Bio at this must-attend summit to successfully optimize, accelerate and scale your extracellular vesicle-based therapeutics towards the first clinical approval.

Register now…

­

­

­

Conference: 3rd Annual Gene Therapy Immunogenicity Summit 

­

In the context of ever-increasing gene therapy clinical activity and uncertainty around challenges posed by immune responses to delivery, this summit (October 18-20, 2022) will unite large pharma and innovative biotech’s to ensure that you’re up to speed on the latest approaches to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune-modulatory strategies can help to ensure efficacy and safety and learn the reality of regulatory expectations around immunological assays.
Incorporating insights from leading immunological, bioanalytical, and translational experts, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing clinical mitigation strategies to address immunogenicity.
With 35+ industry-based speakers covering pre-clinical and clinical immunogenicity challenges over 2 tracks and 3 packed days of content, don’t miss your chance to join over 100+ fellow industry experts to network in person and share your research as you seek new and improved ways of predicting immunogenicity in the clinic to ultimately ensure the safety and efficacy of gene therapies.

Register now…

­

­

­

Conference: Innate Killer Summit Europe

­

The Innate Killer Summit Europe (18-20th October 2022), built with 24+ expert speakers and over 28 sessions, is your ultimate opportunity to streamline your preclinical development and supercharge your preclinical to commercial scale strategy.

Register now…

­

­

­

Conference: Oncology at Total Health 2022

­

With overall need for oncology services increasing, and the supply of oncologist professionals rapidly being drained, the pressure to meet the pent-up demand is shooting up to the point of no return. Uncovering new ways in which we can support oncology care providers to reduce burden, outsource workloads and remove the complexity behind treatment planning is needed now more than ever.

The pandemic has shown us what’s possible when medical innovation is paralleled by further investment, greater collaboration, and a sense of urgency - Science has the medical answers to beating Cancer, but the operational efficiency of Cancer care systems will determine patient outcomes.

In this light, Reuters Events: Oncology at Total Health 2022 (20-21 October 2022), is much more than just a conference; it’s the origin of change. We empower policy makers, payers, providers, pharma companies and patients to unleash the power of organizational change, enable cross-industry partnerships and investments, accelerate treatment pathway digitization, and transition to value-based reimbursement models.  

Register now…

­

­

­

Conference: 4th TIL Therapies Summit

­

Commercialization looks set to propel TIL therapy into the spotlight for adoptive cell therapy, and the 4th TIL Therapies Summit arrives to finally reunite the community in-person this October 24-26.
Built to ensure your core functions are up to speed on the cutting-edge advances in TIL therapy, this year focuses on full end-to-end content across pre-clinical research, clinical translation, process development and manufacturing, ensuring you can strengthen your pipelines and achieve your 2022/23 milestones.
Showcasing clinical benefits in multiple indications, discussing novel CRISPR engineering, debating combination approaches and clinical outcomes to enhance TIL function in the hostile tumor microenvironment, this is a conversation not to miss.
With 20+ world-class speakers and over 100 senior attendees from around the globe, join the largest community of TIL-targeted drug development experts for a deep dive into clinical development progress, lessons learnt and novel strategies to maximize TIL-targeting to recognize and capitalize on this outstanding approach in adoptive cell therapy!

Register now…

­

­

­

Conference: 6th Annual Gene Therapy for Rare Disorders Europe Summit

­

Welcome to the 6th Annual Gene Therapy for Rare Disorders Europe Summit 2022 (25 - 27 October, 2022). Gain European Regulatory Clarity to Progress Efficient & Robust Gene Therapies for Rare Disease
As more and more companies gear up for clinical activity and near approval decisions, the need to have an in-depth understanding of the regulatory frameworks and how these feed into clinical development and manufacturing processes is as vital as ever.
This year’s summit is dedicated to gaining European regulatory clarity to progress efficient and robust gene therapies for rare diseases. By giving voice to pioneering drug developers with success stories to share, experts in regulatory affairs, and the regulators themselves, this meeting is your comprehensive guide to unpicking the thorniest regulatory challenges.
Across three carefully curated days, this streamlined one-track summit will unite key gene therapy leaders from large pharma to ground-breaking biotech, academics to exciting service providers, all with the purpose of paving a way forward to successfully launch gene therapy products in Europe.

Register now…

­

­

­

Upcoming conferences and meetings

­

  • 15 - 18 August 2022 - Bioprocessing Summit - Gene and Cell therapies - Boston, MA
  • 22 - 23 August 2022 - The Cell Therapy Durability Response Summit - Boston, MA
  • 24 - 25 August 2022 - Vector Development for Cell and Gene Therapy Summit - Boston, MA
  • 6 - 8 September 2022 - Optimizing AAV Safety Summit - Boston, MA
  • 13 - 16 September 2022 - 3rd Annual Gene Therapy for Ophthalmic Disorders - Boston, MA
  • 19 - 23 September 2022 - 7th Annual CAR-TCR Summit - Boston, MA
  • 20 - 21 September 2022 - Cell & Gene Therapy USA 2022 - Online event
  • 20 - 22 September 2022 - mRNA Process Development & Manufacturing Summit - Boston, MA
  • 21 - 22 September 2022 - Oligonucleotide Therapeutics and Delivery 2022 - London, UK
  • 26 - 28 September 2022 - International Human Gene Therapy Conference - Melbourne, Australia
  • 27 - 30 September 2022 - Cell & Gene Therapy Manufacturing & Commercialization US - Boston, MA & Online
  • 4 – 6 October 2022 - 4th Exosome Based Therapeutic Development Summit: Gene delivery therapies - Boston, MA
  • 11 – 14 October 2022 - XXIX Congress of the European Society of Gene and Cell Therapy (ESGCT) - Edinburgh, UK
  • 13 - 14 October 2022 - Global Bioprocessing Summit and Expo - ATMP Development - Berlin, Germany
  • 18 - 19 October 2022 - iPSC-Derived Immunotherapies Congress - Boston, MA
  • 18 - 20 October 2022 - 3rd Annual Gene Therapy Immunogenicity Summit - Boston, MA
  • 18 - 20 October 2022 - Process Development for Cell Therapies Summit - Boston, MA
  • 18 - 20 October 2022 - Innate Killer Summit Europe - London, UK
  • 20 - 21 October 2022 - Reuters Events: Oncology at Total Health 2022 - T-cell therapies - Chicago, USA
  • 24 - 26 October 2022 - 4th TIL Therapies Summit - Boston, MA
  • 25 - 27 October 2022 - 6th Annual Gene Therapy for Rare Disorders Europe Summit 2022 - London, UK
  • 2 – 3 November 2022 - Onco Cell Therapy Summit 2022 - Amsterdam, The Netherlands
  • 7 – 8 November 2022 - 8th Annual Cell & Gene Therapy Manufacturing Congress - London, UK
  • 8 – 10 November 2022 - Emerging Non-Coding RNA Therapeutics Summit - Boston, MA
  • 16 – 17 November 2022 - 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit - Vienna & Online
  • 16 – 18 November 2022 - Joint meeting of the Australasian Gene and Cell Therapy Society - Melbourne, Australia
  • 17 – 18 November 2022 - 6th Aseptic Processing Summit - Manufacturing ATMPs and vaccines - Vienna & Online
  • 28 November - 1 December 2022 - 4th Annual Gene Therapy Analytical Development - Boston, MA
  • 5 - 8 December 2022 - Cell & Gene Therapy Manufacturing & Commercialization Europe - Amsterdam & Online

­


Advertise on this site?